Who Paid My Doc
David Rogers
Ophthalmology Columbus, OH Medical Doctor
NPI 1326076647 CMS profile 884605
555 S 18Th St Ste 4C, Columbus, OH 43205
General payments
$8,891
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$1,455,196
Through program year 2025, David Rogers of Columbus, OH is reported in the CMS Open Payments database as having received $8,891 across 13 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,455,196 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 88th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $6,916 | 6 | |
| 2023 | General | $532 | 2 | |
| 2022 | General | $43 | 1 | |
| 2021 | General | $700 | 2 | |
| 2020 | General | $700 | 2 |
Beside peers
- David Rogers
- Ophthalmology median
- Middle half of Ophthalmology
- National median
In program year 2025, general payments to David Rogers were reported at $6,916. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.
Show as a table
| Year | David Rogers | Ophthalmology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $258 | $104–$655 | $163 |
| 2020 | $700 | $126 | $45–$321 | $114 |
| 2021 | $700 | $205 | $76–$534 | $132 |
| 2022 | $43 | $266 | $100–$678 | $149 |
| 2023 | $532 | $308 | $117–$745 | $160 |
| 2024 | $0 | $340 | $127–$846 | $164 |
| 2025 | $6,916 | $384 | $136–$917 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 9 billing codesPaid by Medicare
$4,431
Medicare patients
21
Services billed
61
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 57% | |
| Atrial fibrillation | 0% | |
| Alzheimer's or dementia | 0% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
13 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Ophthalmology in Ohio
Related records
Ophthalmology in Ohio
Practitioners in the same specialty and state, ranked by reported value.
All Ophthalmology
Everyone recorded under this specialty, nationwide.
Doctors in Ohio
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.